Arash Sadeghian
Optometrist · Corona, CANPI 1447392246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Lumenis BE Inc at 26.1% of the total. 2025 is the largest year on record at $5,483, 2.6 times the $2,119 reported in 2019. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$4K
- Sun Pharmaceutical Industries Inc.$2K
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- AbbVie$835
- Aerie Pharmaceuticals, Inc.$716
- plus $6K from 24 others
What the payments were for
- Consulting fees$7955%
- Speaking & faculty fees$5003%
- Food & beverage$14,68891%
- Education$520%
- Gifts$170%
- Entertainment$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 2 | $4,219 |
| Sun Pharmaceutical Industries Inc. | 58 | $1,700 |
| Bausch & Lomb Americas Inc. | 98 | $1,256 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 45 | $1,001 |
| AbbVie(2 entities) | 31 | $835 |
| Aerie Pharmaceuticals, Inc. | 13 | $716 |
| Harrow Eye, LLC | 22 | $662 |
| Novartis | 35 | $646 |
| Oyster Point Pharma, Inc. | 12 | $602 |
| Eyevance Pharmaceuticals LLC | 23 | $558 |
| Alcon | 18 | $540 |
| Coopervision Inc. | 17 | $537 |
| Optovue, Inc. | 1 | $500 |
| Glaukos Corporation | 5 | $429 |
| Kala Pharmaceuticals, Inc. | 15 | $332 |
| Shire North American Group Inc | 17 | $304 |
| Sight Sciences, Inc. | 2 | $273 |
| Biotissue Holdings Inc. | 8 | $267 |
| Dompe US, Inc. | 2 | $159 |
| Regeneron Healthcare Solutions, Inc. | 1 | $134 |
| Optos, Inc. | 2 | $107 |
| Topcon Healthcare, Inc. | 1 | $90 |
| Tarsus Pharmaceuticals, Inc. | 2 | $57 |
| Ascendis Pharma Endocrinology Inc | 1 | $52 |
| ABB Con-cise Optical Group LLC | 3 | $46 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $39 |
| Johnson & Johnson Vision Care, Inc. | 1 | $38 |
| Amgen | 1 | $29 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$4,000
- iVue$500
- Rocklatan$500
- CEQUA$478
- TYRVAYA$364
- VYZULTA$275
- XELPROS$230
- BROMSITE$230
- M22$219
- CE-marked KXLA system$171
- TearCare SmartLid$148
- TEARCARE(TM) (2.2) SYSTEM KIT$148
- iStent inject Trabecular Micro-Bypass Stent System$137
- EYLEA$134
- Oxervate$125
- MIEBO$125
- XIIDRA$125
- OMNI$124
- DURYSTA$124
- Wavelight$120
How this compares
$16,159 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 70 | $55,540 |
| VevyeCyclosporine | 37 | $28,297 |
| VyzultaLatanoprostene Bunod | 53 | $21,166 |
| CequaCyclosporine | 25 | $13,763 |
| RestasisCyclosporine | 13 | $10,359 |
| LumiganBimatoprost | 13 | $8,594 |
| Cyclosporine | 13 | $7,896 |
| Alphagan PBrimonidine Tartrate | 32 | $7,312 |
| AzasiteAzithromycin | 14 | $3,874 |
| Brimonidine Tartrate | 17 | $2,316 |
| Doxycycline Monohydrate | 22 | $801 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $779 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,256 | $76,706123 claims |
| Harrow Eye, LLCVevye | $662 | $28,29737 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $835 | $26,26458 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,700 | $13,76325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in Corona
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
- Steven FerrucciSepulveda$272K
- Katie ChuRosemead$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.